Magnetic resonance imaging is highly sensitive in revealing CNS abnormalities associated with several neurological conditions, but lacks specificity for their pathological substrates. In addition, MRI does not allow evaluation of the presence and extent of damage in regions that appear normal on conventional MRI sequences and that postmortem studies have shown to be affected by pathology. Quantitative MR-based techniques with increased pathological specificity to the heterogeneous substrates of CNS pathology have the potential to overcome such limitations. Among these techniques, one of the most extensively used for the assessment of CNS disorders is magnetization transfer MRI (MT-MRI). The application of this technique for the assessment of damage in macroscopic lesions, in normal-appearing white and gray matter, and in the spinal cord and optic nerve of patients with several neurological conditions is providing important in vivo information-dramatically improving our understanding of the factors associated with the appearance of clinical symptoms and the accumulation of irreversible disability. MT-MRI also has the potential to contribute to the diagnostic evaluation of several neurological conditions and to improve our ability to monitor treatment efficacy in experimental trials.
INTRODUCTION
In many neurological conditions, MRI has proved to be a sensitive tool for detecting CNS abnormalities and their changes over time. Despite such a high sensitivity, conventional MRI (i.e., dual-echo, fast fluid attenuated inversion recovery and T1-weighted scans with or without paramagnetic contrast) does not provide an accurate estimate of the extent and nature of the associated tissue damage. Quantitative MR-based techniques with increased pathological specificity to the heterogeneous substrates of CNS pathology have the potential to overcome such limitations. Among such techniques, magnetization transfer MRI (MT-MRI) has been one of the most extensively applied for the assessment of CNS disorders.
The present review summarizes the major contributions of MT-MRI for the in vivo monitoring of various CNS diseases. Because MT-MRI has been applied primarily to improve our understanding of the pathophysiology of multiple sclerosis (MS), a special focus is devoted to this condition and to allied white matter (WM) disorders.
BASIC PRINCIPLES OF MT-MRI
MT contrast results from the interactions between the protons in free fluid in a tissue and those protons bound in macromolecules. 1 Although the magnetization from these macromolecules cannot be observed directly, proton magnetization is in constant exchange between the free fluid and the macromolecules, and so magnetization saturation and relaxation within the macromolecule affect the observable signal from the free water. 2 MT contrast is achieved by applying a radio frequency (RF) power only to the proton magnetization of the macromolecules. Because, in brain tissue, the free water protons and macromolecular protons have the same central resonance frequency but very different line widths, this can be achieved by shifting the frequency of the saturating RF pulses to one side of the free water resonance line. 3 The RF pulse frequency offset is chosen to minimize direct saturation of the free pool within the constraint of remaining sufficiently small that it is not out of the frequency range of the broad resonance line of the macromolecular spins.
The most general description of the MT effect uses data acquired at a range of saturating powers and offsets, and models the system as two or more compartments. 4 This allows both the relaxation rates of the pools and their relative proportions to be determined. More simply, the MT effect can be characterized by a nonspecific pseudo rate constant (k f ) for the MT process. Note that k f includes both chemical exchange and dipolar coupling between bound and free protons. The k f can be found by measuring the free water signal twice: in the presence and in the absence of the MT saturating pulses. The free water relaxation rate in the presence of the saturating pulses (R 1sat ) must also be measured, in which case
where M 0 is the magnitude of the free water proton signal in the absence of the off-resonance saturating pulses, and M S is the magnitude of the free water proton signal with the off-resonance saturating pulses applied. Note, however, that the above equation is strictly valid only in the case of perfect saturation of the bound pool, a condition that cannot be achieved in vivo on with clinical scanners. If the rate constant is not specifically of interest, then one can calculate the MT ratio (MTR), a simple measure of MT effects:
A low MT ratio (MTR) indicates a reduced capacity of free water to exchange magnetization with the brain tissue matrix with which the water comes into intimate contact. For example, in CSF, where there is almost a complete absence of macromolecules, no exchange can occur, the observable signal is unaffected by the saturation pulses, and the MTR approaches zero. In healthy brain tissue, where M S drops significantly below M 0 as the saturated magnetization is transferred to the observable water, an MTR of up to 40 -50% may be seen, depending on the pulse sequence used.
Although at present nearly all clinical MT-MRI studies are based on MTR measurements, the reduction of the MT phenomenon to a single MTR value has limited the interpretation of the results and the ability to achieve an optimal standardization of MTR measurements across multiple centers. MT-MRI uses off-resonance RF pulses to create contrast, and the MTR values obtained strongly depend on the offset frequency, bandwidth, and average power of the pulses. Differences among centers can be minimized by standardizing the pulse sequence implementation and choice of parameters-although, where multiple scanner types are to be used, this may lead to the use of a lowest common denominator sequence rather than to an optimal one.
ANALYSIS OF MT-MR IMAGES
Once MTR maps have been produced, several approaches can be adopted to analyze disease-related abnormalities on these maps.
1. Region of interest analysis of specific tissues. The region of interest (ROI) approach allows the study of individual lesions and discrete areas of the normal-appearing white matter (NAWM) and gray matter (GM).
2. Analysis of average MTR. An approach based on average MTR of T2-visible or T1-visible lesions (or both) allows obtaining information about the severity of tissue damage of the overall lesion population or of lesions with more severe tissue damage.
3. Contour plotting of MTR. The contour-plotting approach displays the MTR values as an overlay on MR images. 5, 6 In this way, it is possible to detect gradients and boundaries of abnormal MTR that are too subtle to be detected by conventional reading of the MTR maps.
4. Histogram analysis of large portions of brain or cord tissues. The histogram approach encompasses both microscopic and macroscopic lesion burdens in the examined tissue. 7 For each histogram, several parameters can be calculated. 7 The most widely used include the height and position of the histogram peak (i.e., the most common MTR value in the brain) and the average MTR. MTR histograms can be obtained for the whole brain; for specific regions of the brain (e.g., NAWM, GM, frontal lobe, cerebellum, and brainstem), which can be segmented according to standard neuroanatomical references; and for the cervical cord. MTR histogram analysis is a highly automated technique and, as a consequence, intrarater, interrater, and scan-rescan variabilities of MTR histogram-derived metrics are low. 8, 9 5. Voxel-based statistical analysis of MTR images. The voxel-based approach, which uses standardized anatomical spaces and a voxel-by-voxel analysis, allows the investigator to obtain an overall assessment of macroscopic and microscopic damage from the entire brain or from specific brain tissues, such as the GM, while preserving spatial information of lesion location (which is lost with histogram analysis) and without a priori knowledge about lesion distribution.
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MT-MRI IN MS
Studies of individual lesions indicate that MT-MRI is a valuable instrument for grading the severity of intrinsic lesion damage. Homogeneously enhancing lesions, which may represent new active lesions, have significantly higher MTR values than do ring-enhancing lesions, [12] [13] [14] [15] which may represent old, reactivated lesions. The duration of enhancement is also associated with different degrees of MTR changes in new MS lesions: lesions enhancing on at least two consecutive monthly scans have lower MTR than those enhancing on a single scan, 16 suggesting that a longer enhancement in MS lesions may be related to a more severe tissue damage.
That a less-damaged blood-brain barrier (BBB) is associated with milder tissue damage is also indicated by the demonstration that new lesions enhancing after the injection of a standard dose of gadolinium (Gd) have significantly lower MTR values than those enhancing only after a triple dose 17 and by the demonstration that large enhancing lesions tend to have greater MTR reductions than do smaller lesions. 12 On average, MTR drops dramatically when the lesions start to enhance and may show a partial or complete recovery in the subsequent 1-6 six months.
The relatively good preservation of axons that is usual in acute MS lesions 18 and the rapid and marked increase of the MTR are consistent with demyelination and subsequent remyelination, but not axonal loss. Nevertheless, edema and its subsequent resolution may also give rise to the observed pattern of MTR behavior, due to the diluting effect of extratissue water, causing an initial decreased MTR with vasogenic edema, followed by recovery of MTR with resolution of edema. It seems unlikely, however, that edema alone is sufficient to explain these findings, because edema in the absence of demyelination results in only modest MTR reductions. 13, 19 The effect of gliosis on MTR is likely to be marginal, if any: a postmortem study was unable to detect any correlation between MTR and the severity of MS lesion and NAWM gliosis. 20 The application of an MT pulse to postcontrast T1-weighted images has been shown to increase the sensitivity of postcontrast T1-weighted scans for detecting active MS lesions. 21 Established MS lesions have a wide range of MTR values. 22 Hypointense lesions, which are characterized by severe axonal loss and demyelination, 23 have lower MTR values than do lesions that are isointense to NAWM on T1-weighted scans.
14,24 MTR of these T1-hypointense lesions has been found to be inversely correlated with their degree of hypointensity.
14 Decreased MTR has also been found in NAWM areas that are adjacent to focal T2-weighted MS lesions [25] [26] [27] and in WM areas characterized by subtle and diffuse signal intensity changes on T2-weighted MR images (referred as "dirty-appearing" WM). 28 MTR progressively increased with distance from MS lesions to the cortical GM, and MTR was lower for patients with more disabling MS courses. 25 These findings suggest that the actual size of MS lesions is greater than that visible on T2-weighted images and that the demyelinating penumbra detected by MT-MRI might be relevant in determining a patient's disability.
The relative proportion of T2-visible lesions with low MTR values is likely to contribute to the presence and accumulation of disability in patients with MS. Average lesion MTR has indeed been found to be lower in patients with relapsing remitting (RR) MS than in those with clinically isolated syndromes (CIS) suggestive of MS 24, 29 or in those with benign MS. 30 Low average lesion MTR has also been found in patients with secondary progressive (SP) and primary progressive (PP) MS. 31 Furthermore, a 3-year follow-up study showed that newly formed lesions from patients with SPMS have a more severe MTR deterioration than those from patients with mildly disabling RRMS. 32 Patients with cognitive impairment have a significantly lower average lesion MTR than do those without, but average lesion MTR was found to explain only 35% of the total variance in neuropsychological test performance. 33 Average lesion MTR percentage change over a year was found to be an independent predictor of accumulation of disability in the subsequent 7 years in a cohort of patients with CIS, RRMS, and SPMS. 34 The only partial correlation found was between the degree of intrinsic lesion damage, measured using average lesion MTR, and the clinical manifestations of MS; this might be due, on the one hand, to the variable extent of tissue damage outside T2-visible lesions or, on the other, to the fact that intrinsic lesion damage can induce adaptive cortical changes, 35, 36 which in turn have the potential to limit the clinical consequences of subcortical WM damage.
36
MT-MRI OF NORMAL-APPEARING BRAIN TISSUE AND NAWM
Postmortem studies have shown that abnormalities can be detected in NAWM from patients with MS. 37, 38 These abnormalities include diffuse astrocytic hyperplasia, patchy edema and perivascular cellular infiltration. In addition, Arstila et al. 37 described abnormally thin myelin in biopsies from NAWM of MS patients, and signs of axonal damage in MS NAWM have also been detected. 39, 40 Such pathological abnormalities modify the relative proportions of mobile and immobile protons of the diseased tissue, and so it is not surprising that MT-MRI is able to show microscopic damage in NAWM that conventional imaging fails to detect. [25] [26] [27] Decreased MTR values have been found, using ROI and histogram analysis, in normal-appearing brain tissue (NABT) and NAWM of MS patients, 24, 29, 30, [41] [42] [43] [44] [45] [46] [47] which can precede new lesion formation. 48 -51 NABT and NAWM MTR abnormalities have been detected in patients with CIS suggestive of MS, 29, 44, 46 increase progressively in early RRMS 45 and early PPMS, 47 and are more pronounced in SPMS and PPMS patients than in patients with the other main disease phenotypes. 24, 31, [41] [42] [43] Benign MS patients had NABT MTR values significantly higher than those of early RRMS patients. 30 NABT MTR was found to be normal in patients with early-onset MS. 52 In agreement with the notion that NABT and NAWM MTR values differ in the various MS phenotypes, decreased MTR values have been associated with the severity of locomotor disability 11, 42, [53] [54] [55] and cognitive impairment, 33,56 -59 but no correlation has been found with the severity of fatigue. 60 Evidence also suggests that NABT MTR may predict subsequent disease evolution. A significant decline of NABT MTR over time has been shown to occur at a faster rate in patients with SPMS than in patients with other clinical phenotypes. 61 A relationship between the extent of NABT MTR changes in CIS patients and the subsequent evolution to definite MS has been suggested by some authors, 29, 50 but not by others. 62, 63 In patients with established MS, two studies have shown that NAWM MTR predicts the accumulation of clinical disability over the subsequent 5 years. 64, 65 In MS patients, NABT MTR values are only partially correlated with the extent of macroscopic lesions and the severity of intrinsic lesion damage, 31, 66 which suggests that NABT changes do not reflect only wallerian degeneration of axons traversing large focal abnormalities. Indeed, a strong correlation has been found between NABT MTR and brain volume, 66 suggesting that NABT damage is involved in determining irreversible tissue loss in MS.
More recently, in patients with RRMS 35 and PPMS, 67 moderate to strong correlations have also been found between the severity of structural changes of the NABT (as measured using MT-MRI) and the relative activations of several cortical areas located in a widespread network for sensorimotor and multimodal integration, measured using functional MRI. This suggests that not only macroscopic MS lesions, but also subtle NABT changes can cause adaptive cortical reorganization with the potential to limit the functional consequences of MS-related structural damage.
GRAY MATTER
Postmortem studies have shown that MS pathology does not spare cerebral GM. 68 -71 Consistent with this, several studies using different methodologies (ROI, 72 histogram, [72] [73] [74] or voxel-based 10,11 analysis) have shown reduced MTR values in the GM from patients with MS. Reduced GM MTR seems to be present in all MS clinical phenotypes, starting from the earliest clinical stage of the disease. [45] [46] [47] Such GM abnormalities, however, increase with disease duration; for example, they were found to be more pronounced in patients with PPMS or SPMS. 31 The distribution of MTR abnormalities in the different brain GM structures still needs to be defined. In CIS patients with previous optic neuritis, voxel-based morphometry revealed that MTR changes were located mainly in the occipital cortex. 75 In a recent study, a regional pattern of brain MTR decrease more evident in the basal ganglia was found in patients with early MS. 10 By contrast, two other studies, 76, 77 of which one assessed thalamic MTR in early RRMS patients 76 and the other measured MTR in caudate, putamen, globus pallidus and thalamus from RRMS and SPMS patients, 77 found no significant difference between patients and controls. One of the studies, however, showed that the mean thalamic MTR became significantly lower in patients during follow-up. 76 GM MTR changes have been found to correlate with physical disability 47, 73, 74, 78 and cognitive impairment, 11 but no correlation with fatigue has emerged. 79 GM MTR was also found to be an independent predictor of subsequent accumulation of disability in patients with MS monitored for 8 years. 34 The moderate correlation found between the extent of intrinsic GM changes and WM pathology (both focal and what is called diffuse) 47, 72, 73 suggests that MS-related GM abnormalities are only in part due to retrograde or trans-synaptic degeneration of GM neurons secondary to the damage of fibers tranversing diseased WM areas.
MT-MRI FOR MONITORING TREATMENT EFFICACY
An international consensus conference of the White Matter Study Group of the International Society for Magnetic Resonance in Medicine has recommended the use of MT-MRI in the context of large-scale MS trials as an adjunctive measure to monitor disease evolution. 80 As a consequence, ad hoc guidelines for implementing MT-MRI as a part of multicenter clinical trials have been produced. 81 Several MS clinical trials have incorporated MT-MRI, with a view to assessing the effect of treatment on demyelination and axonal loss. To our knowledge, MT-MRI has been used in phase II and phase III trials for RRMS (injectable and oral interferon beta-1a [IFN␤-1a], IFN␤-1b, and oral glatiramer acetate and intravenous methylprednisolone) and SPMS (IFN␤-1b and intravenous immunoglobulins [IVIG] ). Some of these studies were conducted at single centers with small numbers of patients [82] [83] [84] [85] and so were not confronted with problems of standardization of MT acquisition and postprocessing. In multicenter trials, 86, 87 MT-MRI acquisition has been limited to highly specialized MR centers and only subgroups of patients (ϳ50 -100 per trial) have been studied using MT-MRI. Two of these studies with a baselineversus-treatment design have shown that treatment with IFN␤-1b 83 or IFN␤-1a 84 favorably modifies the recovery of MTR values that follows the cessation of Gd enhancement in newly formed lesions from RRMS patients.
These findings suggest that, in addition to its effects in reducing the formation of new lesions, IFN␤ might also act by reducing tissue damage and promoting remyelination within those lesions that still form during therapy. By contrast, Richert et al. 83 did not find any significant difference in the MTR values of NAWM ROIs or in parameters derived from whole-brain MTR histograms 82 in a larger cohort of RRMS patients before or during IFN␤-1b therapy. In the latter study, 82 month-to-month fluctuations of the histogram peak height persisted during the treatment period despite the almost complete suppression of contrast-enhanced MRI activity.
A course of intravenous methylprednisolone (1 g daily ϫ 3 days, followed by 12-day prednisone taper) did not modify favorably the changes of average lesion MTR and whole-brain MTR from 10 MS patients followed for 8 weeks. 85 Two studies assessed MT changes in a relatively large cohort of IFN␤-1b-treated 86 and IVIGtreated 87 patients participating in multicenter placebocontrolled trials. Neither IFN␤-1b nor IVIG showed an overall effect of worsening of MT-MRI measures, despite a dramatic effect of IFN␤-1b on the formation of new lesions 88 and of IVIG on the accumulation of brain atrophy. 89 Taken together, these various findings confirm that MT-MRI has the potential to improve our ability to investigate the mechanisms of action of experimental treatments on the different aspects of MS pathology.
MT-MRI STUDIES OF THE CERVICAL CORD AND OPTIC NERVES
MT-MRI of the cervical cord and optic nerve presents technical difficulties, mainly because of the size of these two structures and their tendency to move during imaging. Nevertheless, recent work has shown it possible to acquire good-quality MT images of the cervical cord 31,90 -93 and optic nerve. 94 -99 ROI analysis has revealed reduced MTR values in the cervical cord of MS patients, compared with healthy volunteers. 90 Histogram analysis has demonstrated the absence of abnormalities in cord MTR histogram metrics of patients with RRMS, 92 early-onset MS, 52 and CIS. 99 By contrast, cord MTR metrics are markedly reduced in patients with SPMS and PPMS. 31 Cord MTR is only partially correlated with brain MTR, 93 suggesting that MS pathology in the cord is not a mere reflection of brain pathology and that, as a consequence, measuring cord pathology might be a rewarding exercise in terms of understanding MS pathophysiology.
Two ROI-based studies reported abnormal MTR values in the optic nerve after an episode of acute optic neuritis, independent of the presence of T2-visible abnormalities. 94, 95 MTR of the optic nerve has been found to be correlated with the visual evoked potential latency, 94 and with the degree of visual function recovery 96 after an acute episode of optic neuritis. In a 1-year follow-up study of patients with acute optic neuritis, Hickman et al. 97 showed a progressive decline of average MTR of the affected optic nerve, which reached a nadir after ϳ8 months (despite rapid initial visual recovery). In confirmation of these findings, a progressive decrease of mean MTR values of the affected optic nerve was seen over time in 11 patients with a first episode of optic neuritis.
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MT-MRI IN VARIANTS OF MS
Among the variants of MS that have been described, only neuromyelitis optica and acute disseminated encephalomyelitis have been investigated with MT-MRI. Application of this technique for assessment of overall CNS damage in these patients has provided important pieces of information, which might contribute in their diagnostic work up (Table 1) .
In patients with neuromyelitis optica, the MTR of 100 This is in contrast to findings with MS, and therefore the absence of MTR changes in the NAWM of patients with optic neuropathy and myelopathy increases the confidence in making a diagnosis of neuromyelitis optica. 100 More recently, reduced GM-MTR values have been demonstrated in patients with neuromyelitis optica in comparison to healthy controls, 101 challenging the classic notion of a sparing of the brain tissue in the course of neuromyelitis optica. Finally, similarly to MS, decreased cervical cord MTR has been found in these patients. 100 Although the extent of intrinsic lesion damage, as measured with MT-MRI, is similar between patients with acute disseminated encephalomyelitis and those with MS, the NABT and spinal cord seem to be spared from MT-related pathological changes.
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MT-MRI IN OTHER WM DISORDERS AND CONDITIONS ASSOCIATED WITH WM DAMAGE
Isolated myelitis
In patients with isolated myelitis of the cervical and dorsal cord of probable demyelinating origin, MT-MRI abnormalities are limited to the cord and tend to spare the brain.
103,104
CNS vasculitis
Studies of CNS vasculitis have shown that MTR values of T2-visible lesions of patients with systemic lupus erythematosus 105, 106 or other systemic autoimmune diseases (including Wegener's granulomatosis, Behçet's disease, and antiphospholipid antibody syndrome) 106 are significantly lower than those of the NAWM, even if MTR decreases are less pronounced than those seen in patients with MS. In patients with neuro-systemic lupus erythematosus, MTR changes have also been found in the NAWM [105] [106] [107] [108] and have been correlated with the severity of cognitive and neurological impairment, 109 as well as with the activity of the disease. 107 Marked GM-MTR decrease has also been shown in patients with neuro-systemic lupus erythematosus.
110,111
Hypoxic-ischemic cerebral vasculopathies
An important and common differential diagnosis of WM lesions in patients suspected of having MS is the possibility that these lesions can be caused by hypoxicischemic cerebral small-vessel disorders, which are usually asymptomatic, but can also present with migraine, transient ischemic attacks, stroke, or subcortical arteriosclerotic encephalopathy.
Stroke
Although MT-MRI is less sensitive than diffusion tensor MRI for detecting ischemic changes during the acute and subacute phases of a stroke, 112 reduced MTR values have been demonstrated in chronic ischemic lesions, thus suggesting a role for MT-MRI in providing useful pieces of information to estimate the age of cerebral infarcts. 112 In patients with stroke, MTR of the internal capsule was found to be strongly correlated with the severity of motor deficits. 113 In patients with occlusive cerebrovascular disease, a strong correlation has been found between MTR measured from the WM of the affected hemisphere and regional cerebral metabolic rate of oxygen.
114
Migraine
In patients with migraine and WM lesions, MTR values of T2-visible lesions are lower than those of WM from normal controls, but significantly higher than those of MS. 115 No MTR abnormalities have been detected in the NABT 115 and the cervical cord.
116
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy
In WM lesions of patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), 117 a reduction of MTR values with a magnitude comparable to that seen in MS lesions has been found. MT-MRI abnormalities in CADASIL patients are not limited to macroscopic brain lesions, but involve extensively the brain NAWM 117 and the cervical cord.
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In these patients, cord MTR was significantly correlated with the extent of brain lesions (suggesting wallerian degeneration as the most likely substrate of cord MTR changes) 118 and brain NAWM MTR was found to be correlated with the severity of physical disability and cognitive impairment. 
Leber's hereditary optic neuropathy
In patients with Leber's hereditary optic neuropathy, MTR changes seem to be confined to the optic nerves and brain T2-visible lesions, when present. 
Traumatic brain injury (TBI)
In patients with TBI and no brain MRI-visible lesions, MT-MRI can reveal the presence of microstructural tissue damage in regions known to be susceptible to TBIrelated axonal damage, such as the pons and the splenium of the corpus callosum. 120, 121 The correlation between MTR changes and subsequent clinical recovery remains controversial. 120 -122 The detection of abnormal MTR values in the NAWM of TBI patients has been shown to predict a poor clinical outcome, but normal MTR findings are not necessarily associated with a good functional recovery. 120 -122 Contrary to what is seen in MS, 24, 25 there is an abrupt transition of MTR values between macroscopic lesions of patients with TBI and the surrounding NAWM. 6 
Other conditions
Cerebrotendinous xanthomatosis. MTR changes in the NAWM and GM have been found in patients with cerebrotendinous xanthomatosis and have been shown to be correlated with disability.
123
Fabry's disease. Subtle MTR changes have been described in lesions and NAWM of patients with Fabry's disease.
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MT-MRI IN INFECTIOUS DISEASES
Neuroborreliosis
In patients with neuroborreliosis, no MT-MRI abnormalities have been detected in NAWM and GM, nor in the cervical cord. 125 Similarly, no NAWM MTR changes have been detected in patients with post-treatment Lyme disease syndrome, 126 suggesting that this technique might be useful in the diagnostic work-up of patients with neuroborreliosis and T2-visible brain lesions undistinguishable from those of MS.
Human immunodeficiency virus-encephalitis and progressive multifocal leukoencephalopathy
In patients affected by human immunodeficiency virus (HIV)-encephalitis, MTR values of T2-visible lesions are reduced, but to a lesser extent than is observed in MS lesions. 127 MTR changes in the NAWM have been found in patients with HIV-encephalitis, 127, 128 as well as in HIV-infected asymptomatic patients, 128 and have been correlated with the severity of cognitive impairment. 129 In patients with acquired immunodeficiency syndrome, MT-MRI improves the differentiation between progressive multifocal leukoencephalopathy and HIV-associated WM lesions, 127, 130 because MTR values of progressive multifocal leukoencephalopathy lesions are significantly lower than those measured in HIV-associated lesions.
Tuberculosis and other infectious conditions
MT-MRI may be useful to differentiate tuberculosis from similar-appearing infective lesions on MR images, given that the MTR from the thickened meninges of tuberculous meningitis is significantly lower than that measured from the meninges in cryptococcal and pyogenic diseases and significantly higher than that from the meninges in viral meningoencephalitis. 131 In addition, MTR from T2-visible and occult tuberculomas has been reported to be significantly lower than that of WM, but the MTR of T2-hypointense cysticercus granuloma is significantly higher than that of T2-hypointense tuberculoma. 131 Similarly, MTR from tuberculous abscesses is lower than that of pyogenic abscesses. 132 MTR reduction in areas surrounding solitary cysticercal brain cysts was found to correlate with seizure recurrence after stopping antiepileptic treatment.
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MT-MRI AND AGING
Preliminary studies using ROI-based analysis have achieved conflicting results with regard to age-related variations of MTR values in different brain regions. 134, 135 Mehta et al. 134 did not find significant decreases of MTR with increasing age, whereas Silver et al. 135 reported significant age-related MTR changes in the corpus callosum and frontal WM. Studies with histogram-based analysis reported a significant, age-related decrease of average MTR and histogram peak height both in the WM and GM. 136 -139 In elderly subjects with WM hyperintensities (WMHs), the MTR of WMHs is significantly lower than that of the NAWM 140, 141 and correlates with the extent of such abnormalities, suggesting similar causative mechanisms. 140 In addition, significant MTR abnormalities have been detected in the GM of these individuals, compared with healthy elderly subjects without WMHs, 142 suggesting that these GM abnormalities might be the basis of the mild cognitive deficits that have been reported in some of these individuals. The notion that MTR-related abnormalities might contribute to explanation of age-related cognitive deficits is supported by the finding of moderately reduced MTR values in WMHs of patients with vascular dementia.
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MT-MRI IN OTHER CNS DISORDERS
Alzheimer's disease (AD) and other dementias
Compared with sex-and age-matched controls, patients with AD have markedly reduced MTR histogram peak height of the cortical GM and temporal lobe GM. 144 In these patients, a composite MR score based on brain volume and cortical GM MTR histogram peak height was correlated with cognitive impairment (r ϭ 0.65). 144 This observation has been confirmed by two other studies, which also showed, in patients with mild cognitive impairment (MCI), decreased MTR values of the cortical GM and temporal lobe GM, in the absence of significant volumetric changes. 145, 146 Reductions in MTR histogram peak height for whole brain, temporal lobe, and frontal lobe have also been shown both in patients with AD and in those with MCI. 147 Note that, although AD patients had marked volumetric reductions of all the above-mentioned structures, temporal lobe atrophy was detected only in patients with MCI. 147 MT-MRI measures derived from the whole of the brain tissue, as well as those from temporal and frontal lobes taken in isolation, were strongly correlated with global cognitive deterioration and impairment of several functions in both AD and MCI patients. 147 A recent MT-MRI study confirmed that the extent of overall NAWM and GM damage is similar in patients with AD and MCI, 148 again suggesting that occult structural brain changes may be present before the onset of cognitive deficits. Patients with early AD have also been found to have reduced MTR values of the hippocampus. 149 The latter abnormalities may facilitate differentiating AD patients from patients with dementia with Lewy bodies, in which hippocampal MTR abnormalities are less pronounced.
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Huntington's disease
In a study that explored MTR of caudate nuclei, putamen, periventricular WM, and the whole brain in carriers of Huntington mutation, mild decreases of MTR were observed in the striatum and whole brain. 
Parkinson's disease (PD) and allied conditions
Only a few studies have investigated MTR of the brain in patients with PD; all of them used ROI analysis, with conflicting results. In one study, no difference in MTR of the subcortical GM and WM has been found between patients with idiopathic PD and matched controls, whereas patients with PD and dementia had significantly lower MTR in the subcortical WM, including frontal WM and the genu of the corpus callosum, and those with progressive supranuclear palsy had significantly lower MTR in the subcortical GM, including the putamen, globus pallidus and thalamus. 152 In another study, lower MTR values in supratentorial WM and brainstem were found in PD patients without dementia, compared with controls. 153 Eckert et al. 154 demonstrated changes in the MTR values in the globus pallidus, putamen, caudate nucleus, substantia nigra, and WM in idiopathic PD, in multiple system atrophy, and in progressive supranuclear palsy, matching the pathological features of the underlying disorder. More recently, significant reduction of MTR was found in the substantia nigra, red nucleus, and pons in PD patients in the first year of diagnosis, indicating that MTR analysis may be a useful technique in the assessment of damage in patients with early PD. 155 Reduced MTR values have also been found in the pons, middle cerebellar peduncle, putamen and WM of the precentral gyrus in patients with multiple system atrophy. 156 In this latter group of patients, 155 MTR values of the corticospinal tract were significantly lower in those with corresponding pyramidal signs compared with those without; similarly, MTR values of the basal ganglia were significantly lower in patients with corresponding parkinsonism than in those without it.
Amyotrophic lateral sclerosis
Reduced MTR values have been reported in the corticospinal tracts of patients with amyotrophic lateral sclerosis 157, 158 and have been correlated with clinical measures of motor neuron function.
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Epilepsy
Reduced MTR histogram peak height of the whole brain has been reported in patients with nocturnal frontal lobe epilepsy 159 and focal epilepsy, 160 but not in those with idiopathic generalized epilepsy. 160 Reduced MTR values of the amygdala and hippocampus were reported in patients with temporal lobe epilepsy, 161, 162 but the MTR changes were concordant with the electroclinical lateralization in only one of these patients. 162 More recently, a voxel-based morphometry analysis of the distribution of MTR abnormalities in patients with temporal lobe epilepsy and interictal psychosis revealed significant reduction of MTR values in several regions of the temporal lobe in these patients, in the absence of corresponding macroscopic abnormalities in the same regions. 163 
Hydrocephalus
In patients with normal pressure hydrocephalus 164 and chronic obstructive hydrocephalus, 165 MTR abnormalities have been detected in the periventricular NAWM and in the NAWM of the corpus callosum, but no MTR abnormalities have been revealed in the thalami.
Tumors
MT-MRI has been used to investigate the nature of brain tumors in vivo. 166 Meningiomas were found to have, on average, higher MTR values than other tumors, and soft tumors were found to have lower MTR values than hard tumors. 166 The application of an MT pulse to postcontrast T1-weighted images enabled a higher number of lesions to be detected in patients with brain metastases than did plain T1-weighted images, 167, 168 with a sensitivity similar to that achieved with administration of a triple dose of Gd.
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T1-weighted sequences with MT pulse can also contribute to the assessment of patients with tuberous sclerosis. 169, 170 MT-MRI has been proven to be useful for the study of the normal 171 and pathological 172 adenohypophysis. In patients with hyperprolactinemia, the MTR of prolactin-secreting tumors is higher and that of the nonsecreting adenomas is lower than the MTR values of the normal pituitary gland of age-and sex-matched controls. 172 In some patients surgically treated for growth hormone adenomas, increased MTR values were highly suggestive of persistence of adenoma tissue, in agreement with biochemical findings of persisting secretory activity.
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Myotonic dystrophy
Significant MTR reductions of T2-visible lesions and NAWM were seen in patients with myotonic dystrophy and were correlated with the duration of the disease, suggesting that structural changes in the WM of these patients may be progressive. 173 A more recent study showed that neocortical pathology is likely to be impor-tant in this CNS affection, as reflected by the presence of reduced volumes and MTR values in the neocortex of patients with myotonic dystrophy. 174 
Psychiatric disorders
Although not confirmed by all authors, 175 widespread MTR reductions have been reported in the cortex (predominantly in the frontal and temporal regions), but not in the thalami, 176 of schizophrenic patients, 177 from the earliest stages of the disease. 178 Such MTR changes were unrelated to volume reduction. 177 Decreased MTR values have also been found in several WM areas of the temporal and frontal lobes in schizophrenic patients 177, 179, 180 and have been associated with the severity of negative symptoms. 177 In the early stages of the disease, such MTR abnormalities tend to remain stable, as suggested by a recent 3.7-year follow-up study. 181 In patients with bipolar disorders, MTR analysis showed subtle abnormalities in the anterior cingulated and subgyral WM, in the absence of significant volumetric changes in these regions. 182 More recently, MTR abnormalities in several frontotemporal regions have been correlated with decline in intellectual quotient in these patients.
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CONCLUSIONS
Conventional MRI has markedly increased our ability to detect the macroscopic abnormalities of the brain and spinal cord associated with CNS disorders. New quantitative MR approaches with increased sensitivity to subtle NAWM and GM changes and increased specificity for the heterogeneous pathological substrates of CNS lesions may yield information complementary to that from conventional MRI. Especially in patients with MS and other WM disorders, MT-MRI has the potential to quantify the structural changes occurring within and outside T2-visible lesions.
The application of this technique in patients with a variety of neurological conditions has improved dramatically our understanding of the factors associated with the appearance of clinical symptoms and with the accumulation of irreversible disability. MT-MRI also has the potential to contribute to the diagnostic evaluation of a number of neurological conditions and, as has been shown for MS, the MT-MRI technique can improve our ability to monitor treatment efficacy in experimental trials.
